Access the full text.
Sign up today, get DeepDyve free for 14 days.
I. Berquin, B. Pang, Michele Dziubinski, Latanya Scott, Yong Chen, G. Nolan, S. Ethier (2005)
Y-box-binding protein 1 confers EGF independence to human mammary epithelial cellsOncogene, 24
K. Jürchott, S. Bergmann, U. Stein, W. Walther, M. Janz, I. Manni, G. Piaggio, E. Fietze, M. Dietel, H. Royer (2003)
YB-1 as a Cell Cycle-regulated Transcription Factor Facilitating Cyclin A and Cyclin B1 Gene Expression*Journal of Biological Chemistry, 278
K. Kohno, H. Izumi, T. Uchiumi, Megumi Ashizuka, M. Kuwano (2003)
The pleiotropic functions of the Y-box-binding protein, YB-1.BioEssays : news and reviews in molecular, cellular and developmental biology, 25 7
M. Ono, M. Kuwano (2006)
Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting DrugsClinical Cancer Research, 12
Y. Basaki, F. Hosoi, Yoshinao Oda, Abbas Fotovati, Y. Maruyama, Shinji Oie, M. Ono, H. Izumi, K. Kohno, K. Sakai, Tatsu Shimoyama, Kazuto Nishio, M. Kuwano (2007)
Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cellsOncogene, 26
N. Reinmuth, M. Meister, T. Muley, M. Steins, M. Kreuter, F. Herth, H. Hoffmann, H. Dienemann, Michael Thomas (2006)
Molecular determinants of response to RTK‐targeting agents in nonsmall cell lung cancerInternational Journal of Cancer, 119
Y. Oda, Kenichi Kohashi, Hidetaka Yamamoto, S. Tamiya, K. Kohno, M. Kuwano, Y. Iwamoto, T. Tajiri, T. Taguchi, M. Tsuneyoshi (2008)
Different expression profiles of Y‐box‐binding protein‐1 and multidrug resistance‐associated proteins between alveolar and embryonal rhabdomyosarcomaCancer Science, 99
B. Sutherland, J. Kucab, Joyce Wu, Cathy Lee, Maggie Cheang, E. Yorida, D. Turbin, S. Dedhar, Colleen Nelson, M. Pollak, H. Grimes, K. Miller, S. Badve, D. Huntsman, C. Blakegilks, Min Chen, C. Pallen, S. Dunn (2005)
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cellsOncogene, 24
M. Kuwano, Y. Oda, H. Izumi, Song‐Ju Yang, T. Uchiumi, Y. Iwamoto, M. Toi, T. Fujii, H. Yamana, H. Kinoshita, T. Kamura, M. Tsuneyoshi, K. Yasumoto, K. Kohno (2004)
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance.Molecular cancer therapeutics, 3 11
D. Faury, A. Nantel, S. Dunn, M. Guiot, T. Haque, P. Hauser, M. Garami, L. Bognár, Z. Hanzély, P. Liberski, E. López-Aguilar, E. Valera, L. Tone, A. Carret, R. Maestro, M. Gleave, J. Montes, T. Pietsch, S. Albrecht, N. Jabado (2007)
Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 10
T. Ohga, K. Koike, M. Ono, Y. Makino, Y. Itagaki, M. Tanimoto, M. Kuwano, K. Kohno (1996)
Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light.Cancer research, 56 18
(1998)
Philadelphia: Lippincott-Raven
J. Engelman, P. Jänne (2008)
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung CancerClinical Cancer Research, 14
Author Simpson (1951)
The Interpretation of Interaction in Contingency TablesJournal of the royal statistical society series b-methodological, 13
Akira Hirata, F. Hosoi, M. Miyagawa, Shu-ichi Ueda, S. Naito, T. Fujii, M. Kuwano, M. Ono (2005)
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.Cancer research, 65 10
Joyce Wu, Cathy Lee, Daniel Yokom, Helen Jiang, Maggie Cheang, E. Yorida, Dmitry Turbin, I. Berquin, Peter Mertens, Thomas Iftner, C. Gilks, Sandra Dunn (2006)
Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.Cancer research, 66 9
G. Schaefer, Lihua Shao, K. Totpal, R. Akita (2007)
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.Cancer research, 67 3
K. Shibahara, K. Sugio, T. Osaki, T. Uchiumi, Y. Maehara, K. Kohno, K. Yasumoto, K. Sugimachi, M. Kuwano (2001)
Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 10
J. Engelman (2007)
The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung CancerClinical Cancer Research, 13
F. Cappuzzo, L. Toschi, I. Domenichini, Stefania Bartolini, G. Ceresoli, Elisa Rossi, V. Ludovini, A. Cancellieri, Elisabetta Magrini, Lynne Bemis, Wilbur Franklin, L. Crinò, P. Bunn, Fred Hirsch, Marileila Varella-Garcia (2005)
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patientsBritish Journal of Cancer, 93
M. Janz, N. Harbeck, P. Dettmar, U. Berger, A. Schmidt, K. Jürchott, M. Schmitt, H. Royer (2002)
Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1International Journal of Cancer, 97
K. Matsumoto, A. Wolffe (1998)
Gene regulation by Y-box proteins: coupling control of transcription and translation.Trends in cell biology, 8 8
T. Kamura, H. Yahata, S. Amada, S. Ogawa, Takanori Sonoda, H. Kobayashi, Masamune Mitsumoto, K. Kohno, M. Kuwano, H. Nakano (1999)
Is nuclear expression of Y box‐binding protein‐1 a new prognostic factor in ovarian serous adenocarcinoma?Cancer, 85
T. Uchiumi, A. Fotovati, T. Sasaguri, K. Shibahara, T. Shimada, T. Fukuda, Takanori Nakamura, H. Izumi, T. Tsuzuki, M. Kuwano, K. Kohno (2006)
YB-1 Is Important for an Early Stage Embryonic DevelopmentJournal of Biological Chemistry, 281
T. Fujii, A. Kawahara, Y. Basaki, S. Hattori, Kazutaka Nakashima, K. Nakano, K. Shirouzu, K. Kohno, T. Yanagawa, H. Yamana, K. Nishio, M. Ono, M. Kuwano, M. Kage (2008)
Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.Cancer research, 68 5
S. Bergmann, B. Royer-Pokora, E. Fietze, K. Jürchott, B. Hildebrandt, D. Trost, F. Leenders, J. Claude, F. Theuring, R. Bargou, M. Dietel, H. Royer (2005)
YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification.Cancer research, 65 10
A. Stratford, Golareh Habibi, A. Astanehe, Helen Jiang, K. Hu, E. Park, Ashleen Shadeo, Timon Buys, Wan Lam, Trevor Pugh, Marco Marra, Torsten Nielsen, U. Klinge, Peter Mertens, Samuel Aparicio, S. Dunn (2007)
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapyBreast cancer research : BCR, 9
Y. Oda, Y. Ohishi, Y. Basaki, Hiroaki Kobayashi, T. Hirakawa, N. Wake, M. Ono, K. Nishio, M. Kuwano, M. Tsuneyoshi (2007)
Prognostic implications of the nuclear localization of Y‐box‐binding protein‐1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt, LRP/MVP and P‐glycoprotein expressionCancer Science, 98
M. Ladomery, J. Sommerville (1995)
A role for Y-box proteins in cell proliferation.BioEssays : news and reviews in molecular, cellular and developmental biology, 17 1
Z. Lu, J. Books, T. Ley (2005)
YB-1 Is Important for Late-Stage Embryonic Development, Optimal Cellular Stress Responses, and the Prevention of Premature SenescenceMolecular and Cellular Biology, 25
ORIGINAL ARTICLE Nuclear Y-Box Binding Protein-1, a Predictive Marker of Prognosis, Is Correlated with Expression of HER2/ErbB2 and HER3/ErbB3 in Non-small Cell Lung Cancer Masaki Kashihara, MD,*† Koichi Azuma, MD, PhD,‡ Akihiko Kawahara, PhD,§ Yuji Basaki, PhD,* Satoshi Hattori, PhD,¶ Takashi Yanagawa, PhD,¶ Yasuhiro Terazaki, MD, PhD,‡ Shinzo Takamori, MD, PhD,‡ Kazuo Shirouzu, MD, PhD,‡ Hisamichi Aizawa, MD, PhD,‡ Kenji Nakano, MD, PhD, Masayoshi Kage, MD, PhD,§#Michihiko Kuwano, MD, PhD, and Mayumi Ono, PhD,* n 26) but not between those with high and those with low Introduction: Nuclear expression of Y-box binding protein-1 expression of EGFR, HER2, HER3, and c-Met. (YB-1) is closely associated not only with global drug resistance and Conclusion: Nuclear YB-1 expression might be essential for the expression of several growth factor receptors in various human malignant phenotype in lung cancer patients and might be an malignancies but also with overall patient survival. important biomarker for the development of therapeutic strategy Methods: The effect of YB-1 knockdown on expression of epider- against NSCLC. mal growth factor receptor (EGFR) family proteins was examined Key Words: YB-1, NSCLC, HER2, HER3. by Western blot using human lung cancer cell lines. Immunohisto- chemistry was used to evaluate the expression
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Sep 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.